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Bacterial translocation in liver cirrhosis: Site and role
in ﬁbrogenesis
JOURNAL OF HEPATOLOGYTo the Editor:
I read with great interest the comprehensive review byWiest and
colleagues [1] on pathological bacterial translocation in liver
cirrhosis. They remarkably analyzed the compartments involved
and their inﬂuencing factors. My concern regards the possible
site(s) of bacterial translocation (BT), and the role of BT in the
progress of both precirrhotic chronic liver damage, particularly
ﬁbrosis, and installed liver cirrhotic lesions themselves.
Regarding the site of bacterial translocation in cirrhosis, the
authors rightly outline that, whereas small intestinal bacterial
overgrowth has the greatest potential for promoting BT and
bacteria causing spontaneous infections are most frequently
exactly those overgrowing in the small intestine [2,3], studies
of experimental liver injury in mice revealed that the cecum
and the colon might be the sites with largest rate of BT and
increase in intestinal permeability [1]. Data in humans were lack-
ing. A recent in vivo human study, not referenced in the Wiest’s
review [1], has reported that colonic permeability was increased
in patients with compensated liver cirrhosis, as compared to
matched controls using a multisugar test, whereas gastroduode-
nal and small intestine permeability were not altered [4].
Whether or not these changes preceded alterations of the gut
microbiome is not known.
A second point of increasing importance, not discussed in the
review [1], regards the experimental role of inﬂammasomes at
the colonic level in both local microbiota taxonomy and potential
translocation associated with chronic precirrhotic liver disease,
namely non-alcoholic fatty liver disease (NAFLD) and non-alco-
holic steatohepatitis (NASH). There is suggestive evidence thatJournal of Hepatology 2Open access under CC BY-NC-ND license.a deﬁciency in components of two inﬂammasomes (NLRP6 and
NLRP3) – which are large multiprotein complexes that sense
intracellular danger signals via NOD-like receptors (NLRs), the
sensor, NLR, forming a complex with the effector molecule, pro-
caspase-1, with or without the contribution of an adapter mole-
cule, such as the apoptosis-associated speck like CARD-domain
containing protein (ASC) – normally acting as sensors of endoge-
nous or exogenous pathogen-associated molecular patterns
(PAMPs) and regulators of the colonic microbiota, leads to dysbi-
osis associated with aggravation of NAFLD and progression to
NASH [5]. Thus, members of the altered colonic microbiota in
inﬂammasome-deﬁcient mice may promote a signalling cascade
in the liver upon translocation, resulting in progression to NASH
in susceptible animals. Toll-like receptors (TLRs) have a major
role in NAFLD pathophysiology due to the liver’s exposure to rel-
atively large amounts of PAMPs derived from the intestine and
delivered via the portal circulation. Intact bacteria or bacterial
products derived from the intestine trigger TLR4 and TLR9 activa-
tion, which results in an increased rate of chronic liver disease
progression in mice that house a colitogenic gut microbiota asso-
ciated with inﬂammasome deﬁciency [5]. Indeed bacterial over-
growth, including in colon [7], is particularly important in
patients with a leaky gut because it increases the luminal amount
of PAMPs. It is noteworthy that mice deﬁcient in sensing PAMPs
or downstream signaling are resistant to NASH [6].
Finally, the consequences of intestinal dysbiosis or bacterial
overgrowth associated with gut leakage may not be limited to
infectious complications, as spontaneous bacterial peritonitis,
due to translocation. Animal studies have clearly pointed that014 vol. 61 j 706–716 709
intestinal microbiota may contribute to progression of chronic
liver damage, especially liver ﬁbrogenesis [8], which in turn
may aggravate not only installed cirrhotic lesions through
increased inﬂammation and ﬁbrosis, but also accelerate or
provoke progression of NASH and alcoholic steatohepatitis to
cirrhosis. Thus, the role, in humans, of BT in the progression of
chronic hepatic damage, both in installed cirrhosis and precirrh-
otic lesions, may appear of paramount importance, in conjunction
with persistent alcohol consumption in cases of alcoholic chronic
liver disease and cirrhosis. There is increasing suggestive evi-
dence that bacterial translocation and intestinal ﬂora dysfunction
are associated with the development of liver ﬁbrosis [9], and that
bacteria and microbial products, including endotoxins – like
lipopolysaccharides (LPS) macromolecules, the major molecular
component of the outer membrane of Gram-negative bacteria –,
bacterial DNA or microbial metabolites – like ethanol produced
by the intestinal microbiome or choline – may contribute to the
pathogenesis of NAFLD and NASH, and presumably to progression
to overt cirrhosis due to increased ﬁbrogenesis [6]. Finally, this
clearly suggests the possible associated role of chronic, repetitive
BT, not only in mesenteric lymph nodes but also in portal blood
and the liver itself [10], as elicited by a chronically leaky intestine
(which may precede and/or be the consequence of cirrhosis and
be aggravated – in alcohol-induced chronic liver disease – by per-
sistent chronic alcohol consumption), in cirrhosis pathogenesis
itself.
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Reply to: ‘‘Bacterial translocation in liver cirrhosis: Site
and role in ﬁbrogenesis’’
To the Editor:
We greatly appreciate the comments raised by Dr Matuchansky
regarding our recent review on pathological bacterial transloca-
tion (BT) in liver cirrhosis [1]. As for the site of BT in cirrhosis
we acknowledge the investigation in compensated cirrhotic
patients utilizing a multisugar test [2]. The study described by
Dr Matuchansky reports in cirrhotic individuals an increased
sucralose/erythritol ratio in 5–24 h urine (supposed to indicate
colonic permeability) whereas the lactulose/rhamnose ratio in
0–5 h urine (supposed to represent small intestinal permeability)
was not altered. This study has not been cited by us due to (i) the
fact, that any information gained by using sugar tests most likely
does not reﬂect permeability to macromolecules such as bacteria
and/or bacterial cell wall components, (ii) criticisms related to
methodological issues in performance of those sugar tests
[3–5], and ﬁnally (iii) the limitation in references to be used.
Sugars utilized in those permeability tests are very small mole-
cules (182–400 Da) whose passage across the mucosal barrier is
not necessarily related to structural damage in the tight junction
barrier that permits increased penetration of large molecules
(e.g., lipopolysaccharide can reach up to 100,000 Da). Moreover,
although not convincingly proven at least for living bacteria, like-
wise larger in size than mono-/disaccharides, BT occurs most
likely via transcytosis (Fig. 1). Transcytosis of vital bacteria how-
ever is complex, includes active sampling by dendritic cells and
transport across M cells as well as epithelial cells all of which is
regulated different from transport of sugars in terms of initiation,
kinetics and host response. Therefore, also others have proposed
that measuring permeability to small sugar molecules does not
correlate with gut dysbiosis, endotoxin release, microbial translo-
cation and/or activation of the mucosal immune system [6,7].
Mucosal defense mechanisms (e.g., number and secretion of
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